Teriparatide Does Not Exacerbate Bone Metastases in Breast Cancer Bone Metastasis Model
In Vivo · 2025
DOI: 10.21873/invivo.13992 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2025. Verfasst von Takashi Kawaragi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan; kawaragi@med.akita-u.ac.jp. Hauptthemen laut MEDLINE: Teriparatide, Bone Neoplasms, Breast Neoplasms, Bone Density Conservation Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: Breast cancer frequently metastasizes to bone, and chemotherapy and hormone therapy can increase osteoporosis risk. Teriparatide (TPTD), an osteoporosis treatment that promotes bone formation, is contraindicated in patients with bone metastases due to concerns about osteosarcoma in animal studies. However, its effects on metastatic bone tumors remain unclear. This study aimed to evaluate TPTD's effects on breast cancer bone metastases using a mouse model. MATERIALS AND METHODS: C57BL/6 mice were injected with E0771 breast cancer cells to establish bone metastasis and breast cancer models. Mice were assigned to the vehicle-treated group (control) or to the TPTD-treated group (80 μg/kg, subcutaneously three times weekly). Tumor weight, volume, bone destruction, pathological fractures, distant metastasis, tumor proliferation (Ki-67, BrdU), and bone microstructure were assessed at 4 and 6 weeks. RESULTS: In both models, no significant differences in tumor weight or volume were observed between the TPTD and control groups. In the bone metastasis model, bone destruction and pathological fractures were not significantly different. No distant metastasis was observed and there were no significant differences in the percentages of Ki-67-positive and BrdU-positive cells in both models. In the bone microstructure analysis at 6 weeks post-injection, bone volume/tissue volume and trabecular thickness increased in the bone metastasis model in the TPTD group (p=0.02 and p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan; kawaragi@med.akita-u.ac.jp.
- Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
- Department of Orthopedic Surgery, Akita Kousei Medical Center, Akita, Japan.
- Department of Orthopedic Surgery, Omori Municipal Hospital, Akita, Japan.
Zitieren
APA
Kawaragi, T., Tsuchie, H., Nagasawa, H., Hongo, M., Kasukawa, Y., Nozaka, K., Kasama, F., Oya, K., Watanabe, M., Tominaga, K., & Miyakoshi, N. (2025). Teriparatide Does Not Exacerbate Bone Metastases in Breast Cancer Bone Metastasis Model. In Vivo. https://doi.org/10.21873/invivo.13992
Vancouver
Kawaragi T, Tsuchie H, Nagasawa H, Hongo M, Kasukawa Y, Nozaka K, et al. Teriparatide Does Not Exacerbate Bone Metastases in Breast Cancer Bone Metastasis Model. In Vivo. 2025. doi:10.21873/invivo.13992
BibTeX
@article{Kawaragi2025,
author = {Kawaragi, Takashi and Tsuchie, Hiroyuki and Nagasawa, Hiroyuki and Hongo, Michio and Kasukawa, Yuji and Nozaka, Koji and Kasama, Fumihito and Oya, Keita and Watanabe, Manabu and Tominaga, Kenta and Miyakoshi, Naohisa},
title = {Teriparatide Does Not Exacerbate Bone Metastases in Breast Cancer Bone Metastasis Model},
journal = {In Vivo},
year = {2025},
doi = {10.21873/invivo.13992}
}
EUVIMED